BMY Company Profile and Key Details

Q: Who are the executives of BMY?

Ms. Sandra Leung Esq.Executive Vice President & Gen. CounselMr. Rupert Vessey BCH, BM, DPHIL, M.A.Executive Vice President and Pres of Research & Early Devel.Dr. Giovanni Caforio M.D.Chairman & Chief Executive OfficerDr. Christopher S. BoernerExecutive Vice President & Chief Commercialization OfficerMr. Jitendra TyagiHead of US Drug Makers - IndiaMr. Samit Hirawat M.D.Executive Vice President & Chief Medical Officer of Drug Devel.Mr. David V. ElkinsExecutive Vice President & Chief Financial OfficerMs. Cari GallmanSenior Vice President & Chief Compliance and Ethics OfficerMr. Timothy PowerVice President & Head of Investor RelationsMs. Ann M. Powell JudgeExecutive Vice President & Chief HR OfficerMr. Greg MeyersExecutive Vice President and Chief Digital & Technology OfficerDr. Christopher S. Boerner Ph.D.Executive Vice President, Chief Operating Officer & DirectorDr. Fouad Namouni M.D.Pres of R&D

NYSE : BMY

Bristol-Myers Squibb

$59.60

-2.13-3.45%

At Close 4:00 PM

70.24

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Bristol-Myers Squibb Company (BMY) stock declined over -3.45%, trading at $59.60 on NYSE, down from the previous close of $61.73. The stock opened at $60.31, fluctuating between $59.10 and $60.58 in the recent session.

Stock Snapshot

61.73

Prev. Close

121.37B

Market Cap

59.1

Day Low

17.23

P/E Ratio

3.46

EPS (TTM)

6.24

Cash Flow per Share

60.31

Open

2.04B

Number of Shares

60.5751

Day High

99.82%

Free Float in %

14.52

Book Value

11.48M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	60.23	60.58	59.10	59.60	13.49M
Apr 01, 2026	61.21	62.23	60.87	61.73	9.87M
Mar 31, 2026	60.20	61.13	59.92	60.65	12.73M
Mar 30, 2026	59.65	60.06	59.08	59.73	16.41M
Mar 27, 2026	59.61	59.69	58.37	58.54	7.91M
Mar 25, 2026	57.79	59.39	57.79	58.94	9.04M
Mar 24, 2026	56.80	57.69	56.45	57.39	11.94M
Mar 23, 2026	58.22	58.25	57.00	57.00	10.07M
Mar 20, 2026	58.26	58.55	56.91	57.48	65.78M
Mar 19, 2026	59.21	59.64	58.09	58.11	12.44M
Mar 18, 2026	59.35	59.67	58.81	59.37	12.16M
Mar 17, 2026	60.13	60.81	59.59	59.71	13.87M
Mar 16, 2026	59.49	59.80	58.87	59.71	8.39M
Mar 13, 2026	59.67	60.07	58.75	59.08	9.37M
Mar 12, 2026	59.17	59.38	58.32	58.95	10.23M
Mar 11, 2026	60.00	60.03	59.27	59.98	8.92M
Mar 10, 2026	60.60	60.96	59.98	60.13	9.68M
Mar 09, 2026	59.92	60.64	59.25	60.63	10.56M
Mar 06, 2026	60.43	60.43	59.45	60.29	11.4M
Mar 03, 2026	61.57	61.95	60.43	61.22	12.42M

Contact Details

Princeton, NJ 08543

United States

https://www.bms.com 609 252 4621

About Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Stock Peers

LLY

-18.9-1.98%

Eli Lilly and Company$935.62 JNJ

-1.08-0.44%

Johnson & Johnson$243.04 ABBV

-6.185-2.88%

AbbVie Inc.$208.80 AZN

2.76+1.37%

AstraZeneca PLC$203.49 NVS

-1.05-0.68%

Novartis AG$154.03 MRK

0.03+0.02%

Merck & Co., Inc.$120.87 GSK

0.7+1.25%

GSK plc$56.69 NVO

0.495+1.36%

Novo Nordisk A/S$36.98 PFE

-0.22-0.77%

Pfizer Inc.$28.33 OGN

0.22+3.58%

Organon & Co.$6.36

Company Overview

Bristol-Myers Squibb Company (NYSE:BMY) closed at $59.60 USD, losing -$2.13 (-3.45%) from the previous close of $61.73. The stock is currently mid-range between its 52-week high and low $42.52 and $62.89. With a market capitalization of about $121.37 billion, Bristol-Myers Squibb Company is classified as a large-cap and shows lower-than-market volatility (beta ~0.27). Key stats such as the average daily volume over the past year has been around 13.60 million shares, in line with its 52-week average. Headquartered in Princeton, NJ, Bristol-Myers Squibb Company operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Christopher S. Boerner, the company employs approximately 34,100 people and listed since June 01, 1972. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 2.79%, SMA50 7.87%, SMA200 23.84%). The stock’s 14-day RSI is 64.14 (firm momentum), while the ATR of 1.28 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -3.52% below its high and over 43.7% above its low. Average 10-day trading volume of 11.63 million shares is below the 3-month average of 13.40 million, indicating normal recent market interest.

Valuation Metrics

Bristol-Myers Squibb Company trades at a P/E ratio of 17.25, slightly below the S&P 500 average, with a price-to-sales ratio of 2.52 and a price-to-book ratio of 6.58 trading at moderately above to book value. The P/FCF stands at 9.45, also below market averages.

Dividend & Fair Value

Bristol-Myers Squibb Company last paid a dividend of 3.12 per share, this equals a trailing yield of roughly 5.52%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $464.62. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of -4.02% annually over the next five years. The latest quarter delivered EPS of $1.63. The next quarter is forecast at $1.45. Next year's EPS is expected at -$2.58. Analyst sentiment is neutral. Analyst rating data shows there are 4 Strong Buy ratings, 4 Buy ratings, 13 Hold ratings, 0 Sell rating and 2 Strong Sell ratings. Price targets range from $75.00 to $34.00. The high target offers 25.84% upside. The low target suggests -42.95% downside. The mean target is $58.09. This offers -2.53% upside. Bristol-Myers Squibb Company earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 30, 2025, missed forecasts by 7.24%. The prior quarter beat by 33.94%. Over the last six quarters, Apple has recorded several small beats. These include 27.78% in July 26, 2024.

Shareholding & Insider Activity

Bristol-Myers Squibb Company has 2.04 billion shares outstanding. The public float is 2.03 billion shares, elevated short interest at 1.46% of float. This equals 29.69 million shares. The short ratio is 2.3 days. Institutional investors hold 82.9% of the float. Insiders own 0.07%. CELGENE CORP /DE/ holds 7.01 million shares, ANDREOTTI LAMBERTO has 935.57 thousand shares and LEUNG SANDRA has 308.63 thousand shares. Over the past six months, insider transactions show net selling. They sold 4.48 thousand shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Bristol-Myers Squibb generated $45.01B in revenue, or $21.66 per share. Gross margin was 76.24%, operating margin 38.31%, and net profit margin 17.83%. Returns are healthy, with ROA at 8.43% and ROE at 27.27%.
On valuation metrics, Bristol-Myers Squibb trades at a P/E of 17.25, P/S of 2.52 and P/B of 6.58. The current ratio is 1.26 and quick ratio is 1.14. Operationally, the company’s inventory turnover is 5.80 and cash conversion cycle is 89.29 days. Debt-to-equity is 2.55, supported by a cash flow-to-debt ratio of 0.30.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Bristol-Myers Squibb posted revenue of $45.01B, down slightly from $26.15B in the prior quarter. Gross profit was $34.31B (margin 76.24%). Operating income was $17.24B (margin 38.3%). Net income was$8.03B (EPS $3.88).
The company ended the quarter with $12.28B in cash and short-term investments, a total debt of $41.46B, and net debt of $30.00B. Total assets were $95.16B, with equity of $29.49B. Financials further reflected stability, with operating cash flow of $13.86B, free cash flow of $12.65B, and capital expenditures of - $1.21B.

Price Forecast & Outlook

Our AI price prediction model suggests that Bristol-Myers Squibb Company stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.48%, with price expected at $63.46 by April 16, 2026, within a range of $62.26 to $64.58 3-Month Outlook: Projected rise of 33.12%, reaching $79.34 by July 01, 2026, with a range of $77.00 to $82.15. 1-Year Outlook: Projected loss of -3.64%, with price at $57.43 by April 02, 2027, within a range of $54.94 to $60.26.

Key Takeaways

Bristol-Myers Squibb Company (NYSE:BMY) shares are flat 0.52% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Bristol-Myers Squibb Company trading at a premium to the broader market with a P/E of 17.25. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $62.51, suggesting 4.88% upside. Our AI forecast model points to short-term strength (6.48% over two weeks), a medium-term rise (33.12% over three months), and a longer-term loss (-3.64% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Bristol-Myers Squibb Company (BMY) stock price?

Bristol-Myers Squibb Company (NYSE: BMY) stock price is $59.60 in the last trading session. During the trading session, BMY stock reached the peak price of $60.58 while $59.10 was the lowest point it dropped to. The percentage change in BMY stock occurred in the recent session was -3.45% while the dollar amount for the price change in BMY stock was - $2.13.

BMY's industry and sector of operation?

The NYSE listed BMY is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Bristol-Myers Squibb Company designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BMY?

Ms. Sandra Leung Esq.
Executive Vice President & Gen. Counsel
Mr. Rupert Vessey BCH, BM, DPHIL, M.A.
Executive Vice President and Pres of Research & Early Devel.
Dr. Giovanni Caforio M.D.
Chairman & Chief Executive Officer
Dr. Christopher S. Boerner
Executive Vice President & Chief Commercialization Officer
Mr. Jitendra Tyagi
Head of US Drug Makers - India
Mr. Samit Hirawat M.D.
Executive Vice President & Chief Medical Officer of Drug Devel.
Mr. David V. Elkins
Executive Vice President & Chief Financial Officer
Ms. Cari Gallman
Senior Vice President & Chief Compliance and Ethics Officer
Mr. Timothy Power
Vice President & Head of Investor Relations
Ms. Ann M. Powell Judge
Executive Vice President & Chief HR Officer
Mr. Greg Meyers
Executive Vice President and Chief Digital & Technology Officer
Dr. Christopher S. Boerner Ph.D.
Executive Vice President, Chief Operating Officer & Director
Dr. Fouad Namouni M.D.
Pres of R&D

How BMY did perform over past 52-week?

BMY's closing price is 40.17% higher than its 52-week low of $42.52 where as its distance from 52-week high of $62.89 is -5.23%.

How many employees does BMY have?

Number of BMY employees currently stands at 34,100.

Link for BMY official website?

Official Website of BMY is: https://www.bms.com

How do I contact BMY?

BMY could be contacted at phone 609 252 4621 and can also be accessed through its website. BMY operates from Route 206 & Province Line Road, Princeton, NJ 08543, United States.

How many shares of BMY are traded daily?

BMY stock volume for the day was 11.48M shares. The average number of BMY shares traded daily for last 3 months was 13.6M.

What is the market cap of BMY currently?

The market value of BMY currently stands at $121.37B with its latest stock price at $59.60 and 2.04B of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	34100
Beta	0.27
Sales or Revenue	$45.01B
5Y Sales Change%	0.574%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

BMY Company Profile and Key Details

Bristol-Myers Squibb

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Dividend & Fair Value

Shareholding & Insider Activity

Technical Performance

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook